A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2022-08-08
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT05399030
- Locations
- 🇨🇳
Jinan Central Hospital, Jinan, China
A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT05372120
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Cancer Hospital.Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT05370755
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
A Study of ICP-033 in Patients With Advanced Solid Tumors
- Conditions
- Patients With Advanced Solid Tumors
- Interventions
- Drug: ICP-033 tablet
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05367232
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Sichuan, Chengdu, China
DDI Study of Orelabrutinib
- Conditions
- Healthy Person
- Interventions
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT05316857
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL)
- Interventions
- Drug: Placebo + R-CHOP
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT05234684
- Locations
- 🇨🇳
PEKING University SHENZHEN Hospital, Shenzhen, Guangdong, China
🇨🇳Sun Yat-sen University Cancer Center Internal medicine department, Guandong, Guangzhou, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia
- Conditions
- Primary Immune Thrombocytopenia
- Interventions
- Drug: Orelabrutinib( lower dose)Drug: Orelabrutinib( higher dose)
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05232149
- Locations
- 🇨🇳
Hainan People's Hospital, HaiKou, Hainan, China
🇨🇳Henan Tumor Hospital, ZhengZhou, Henan, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, ZhengZhou, Henan, China
A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 184
- Registration Number
- NCT05210868
- Locations
- 🇨🇳
Beijing university cancer hospital, Beijing, China
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naÑ—ve Mantle Cell Lymphoma
- Conditions
- Treatment-naÑ—ve Mantle Cell Lymphoma
- Interventions
- Drug: R-CHOP
- First Posted Date
- 2021-09-21
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 356
- Registration Number
- NCT05051891
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Guangzhou First People's Hospital, Guangzhou, Guangdong, China
A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Other: placebo
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT04711148
- Locations
- 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing, China
🇺🇸Neurology Associates, P.C., Lincoln, Nebraska, United States
🇺🇦CNE Regional Clinical Hospital of Ivano-Frankivsk Regional Council, Ivano-Frankivsk, Ukraine